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Copyright © 2008 JCBN Summary We compared three groups of pregnant women: placebo with normotensive
women, group A which included preeclamptics, and group B which comprised preeclamptics
who were supplemented their diets with vitamins C and E. MDA increased from 6.22 ± 2.8
(placebo) to 8.48 ± 1.2 (A) and 8.02 ± 1.8 nmol/gHb (B). NO concentrations were enhanced
from 19.3 ± 4.2 (P) to 23.8 ± 6.4 (A) and 24.1 ± 5.4 μmol/L (B). GSH contents were decreased
from 10.42 ± 2.81 (P) to 8.02 ± 2.92 (A) and 9.39 ± 1.02 μmol/g Hb (B), whereas GSSG
concentrations increased from 0.98 ± 0.28 (P) to 1.24 ± 0.29 (A) and 1.08 ± 0.12 μmol/g Hb (B).
SOD activity decreased 23% in A and 14% in B; GRx decreased 27% in A and 5.5% in B;
GPx decreased 12% in A and 9.6% in B. Catalase activity, however, increased 27% in A and
29% in B as compared to control. Thus, we conclude that the use of vitamins C and E should
be considered for the control of certain important biochemical indices during the development
of preeclampsia; however, further studies are needed to develop methods for the prevention
of preeclampsia in women at high risk.
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Introduction
Preeclampsia is a disorder of pregnancy characterized
by pregnancy-induced hypertension (≥140 mmHg systolic
and/or  ≥90 mmHg diastolic blood pressure), new-onset
proteinuria (≥300 mg protein/day), and edema occurring in
the second half of pregnancy. A significant reduction in the
incidence of preeclampsia was found in women at risk who
were taking vitamins C and E supplements [1]. Antioxidant
supplements in these women were also shown to be
associated with changes in indices of oxidative stress and
placental functions [2]. The vitamin C content in both mild
and severe preeclamptics was found to decrease signifi-
cantly [3] in association with enhanced peroxidation [4] and
lowered thiol levels [5]. The reason for the decrease in
plasma ascorbate is not very clear, but it is consistent with
the hypothesis that uteroplacental perfusion induces oxida-
tive stress and ascorbate consumption [6]. The functional
consequence and the possible role of the decrease in plasma
vitamin C reserves in preeclampsia (PE) are consistent with
the fact that women who ingested less vitamin C than the
recommended daily allowance (8.5 mg) were at a 2-fold
increased risk of developing PE [7]. Currently, there are
several large multicenter trials in progress to determine
the efficacy of antioxidant therapy in the prevention of
preeclampsia. Some negative results [8] have appeared but
more results are awaited finally with interest and will
determine whether antioxidants are effective in preventing
preeclampsia in all populations, or whether such therapy
will be population specific. However, in a recent review,
antioxidant therapy has been suggested and that the prophy-
lactic supplementation of vitamins C and E to pregnant
women is associated with reduced incidence of preeclampsia
and decreased placental and endothelial dysfunction [9].
In preeclampsia, an inverse correlation between vitamin EVit C & E in Regulating Anti and Pro-oxidants in Preeclampsia
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levels and lipid peroxidation has been found [10] suggesting
that vitamin E content in plasma may be used as a prognostic
marker of the likely development of preeclampsia [11]. In
addition, there was a relationship found between the extent
of vitamin E deficiency and increased lipid peroxidation
with enhanced diastolic blood pressure [12]. Thus, decreased
plasma levels of vitamin E could be a contributory factor of
hypertension in preeclampsia, but other studies have not
demonstrated significant differences in plasma vitamin E
levels between normal and preeclamptic women [13].
Moreover, some results are at variance with the prevailing
opinion, since increased plasma levels of vitamin E among
women with preeclampsia as compared to those in normo-
tensive pregnant women have been reported [14]. The latter
study does not support the hypothesis of a causal relation-
ship between decreased dietary vitamin E consumption and
plasma levels and the development of preeclampsia. Thus,
there is not a consensus whether or not these antioxidant
vitamins exert a positive effect to control preeclamptic
developments, especially as they pertain to oxidative stress,
this area needs further study.
During pregnancy, nitric oxide (NO) is one of the most
important relaxing factors of myometrium and also no less
important in the control of blood flow in uterus and placenta.
Oxidative stress developed in preeclampsia may cause
endothelial dysfunction, which may lead to hypertension by
decreased release of vasodilating agents such as NO [15].
NO is a potent vasodilator, and its altered production by the
vascular endothelium may influence the pathogenesis of
preeclampsia [16]. NO regulates leukocyte adhesion to the
endothelium [17] and inhibits vascular smooth muscle cell
proliferation and platelet aggregation [18].
All these functions could be impaired by the consumption
of NO by superoxide anions produced during oxidative
stress, thereby diminishing NO bioavailability. Consistent
with this are the findings of a diminished level of NO in
plasma of preeclamptic women [19]. The status of plasma
NO in preeclampsia is, however, still controversial, and
different groups have reported an increase [20,  21], a
decrease [22, 23] or no change [24] in NOx levels (nitrites
and nitrates, products of stable degradation of NO). A
pathogenic link between serum uric acid is evident from
several studies [25, 26] although it has dual roles. It may
have beneficial functions [acting as an antioxidant] as well
as detrimental actions [to stimulate vascular smooth muscle
cell proliferation and induce endothelial dysfunction] [27].
Thus, our present study also aimed to evaluate NO and uric
acid contents in the plasma of control and preeclamptics
with and without vitamin supplements.
There is no satisfactory treatment of this disease, except
steps to avoid or reduce complications such as hypertension
and eclamptic seizures and early delivery is the only
successful treatment. It is hypothesized that preeclamptic
condition could be explained by alterations in the function of
vascular endothelium and placenta, likely in response to
reduced perfusion, produces circulating factor(s) that alters
endothelial function. These factor(s) are products of oxida-
tive stress [28] and placenta may be the site of the lipid
peroxides [29]. The maternal circulating components were
found to regulate oxidative status of glutathione redox cycle
and adhesion molecule expression in endothelial cells (ECs).
Reduced cellular glutathione, and glutathione reductase
(GRx) activity and altered glutathione peroxidase (GPx)
activity accompany increased inflammatory reactions in
ECs responding to circulatory toxic factors in preeclampsia
[30]. Various studies have highlighted the asymmetric
alterations in the activities of superoxide dismutase (SOD),
catalase, GRx and GPx [5, 30, 31].
In view of the contradictory reports and the seriousness of
preeclampsia, the present study included the determination
of the activities of catalase, SOD, GPx and GRx in the blood
of normal and preeclamptic women with and without
vitamin treatment, along-with the contents of MDA, GSH,
GSSG, GSSG/GSH, NO and uric acid, to collectively
evaluate the roles of vitamins C and E in the regulation of
these factors.
Materials and Methods
Chemicals
ATP, NADPH, GSH, GSSG, Aspergillus nitrate reductase,
and GRx, EDTA, TBA and butylated hydroxytoluene (BHT)
were obtained from Sigma Chemical Company (St. Louis,
MO.). Other chemicals were obtained from E. Merck
(Mumbai, India). All other reagents used were of analytical
grade, either from BDH or SISCO Chemicals (Mumbai,
India).
Subjects
In India, pregnant women are encouraged to book and to
attend regular antenatal check ups. Standard antenatal care is
defined as monthly visits up to 28 weeks; fortnightly until 34
weeks and weekly visits thereafter. The patients in our study
included pregnant women with normal blood pressure,
preeclamptic women admitted to our hospital who had been
or not under regular care, and also those who were referred
from private sectors or primary health centers. The control
group (placebo) consisted of 20 normotensive pregnant
women who were taking regular prenatal vitamins from the
second trimester of pregnancy to delivery.
Group A comprised 22 patients who were not taking any
vitamin supplements, as they belonged to rural areas with
incomes below the poverty-line; they were not booked cases
and they arrived with full term pregnancies just a few days
before delivery. Group B initially consisted of a high number
of patients who were viewed as being at an increased risk ofM. Suhail et al.
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preeclampsia because of factors such as preeclampsia in a
preceding pregnancy, HELLP syndrome, or eclampsia in
any past pregnancy at any gestational stage, and who were
taking additional vitamin supplement (1000 mg vitamin C
plus 400 IU vitamin E per day) from the second trimester of
pregnancy to delivery as mentioned for the controls
(placebo). At a later stage, however, some of the women in
this group did not appear at the time of full term delivery.
For this group, 21 women who had developed severe
preeclamptic conditions agreed to donate blood.
The present study was carried out with the prior approval
of the local ethical committee. All the patients mentioned
above gave their consent in writing, and the objectives of the
study were fully explained to them in detail prior to taking
consent. They were always instructed to fast between 9 p.m.
till retiring in the night before the blood collection. On the
morning of the test they were requested to have only a light
breakfast such as simple toast avoiding any cooked
breakfast, meat, cereals, fruit juices and any nutritional
supplements. They were advised to abstain from having
coffee, chocolates, etc. for at least 2 h before coming for
blood sampling; 8 ml of venous blood was collected in
EDTA-treated tubes from the cubital vein.
Clinical examination and history taking excluded women
addicted to tobacco, patients with diabetes, ischemic heart
disease, a history of stroke, kidney disorders or other
conditions of known free radical etiology. The criteria for
dividing women into normotensive and preeclamptic groups
have been set at a blood pressure of 140/90 mmHg or higher,
proteinuria and edema.
Estimation of plasma levels of NO as stable metabolites
(nitrite + nitrate) [21]
To 300 μl of plasma was added 300 μl of KH2PO4/
K2HPO4 buffer (pH 7.5), 50 μl of 2 mM NADPH, 50 μl of
50 μM FAD and 50 μl of I unit/ml aspergillus nitrate
reductase. This was incubated at room temperature for one
hour followed by the addition of 500 μl of 0.2 M ZnSO4 and
70 μl of 2 M NaOH to deproteinize the sample. After
centrifugation, 0.75 ml of the supernatant was added to 1 ml
of 1% sulphanilic acid (in 4 M HCl). After 10 min at room
temperature, 0.75 ml of freshly prepared 1% N-naphthyl
ethylene diamine was also added. The resultant color
developed was measured at 548 nm using spectrophoto-
meter. Nitrite concentration was calculated using nitrite
standard solution.
Uric acid estimation [32]
Simple colorimetric method was employed. To 4 ml. N/23
sulphuric acid, 0.5 ml. serum was added and mixed. 0.5 ml.
5.6 % sodium tungstate was then added, mixed, and centri-
fuged. 3 ml of the decanted supernatant was placed in a test
tube, to which was added 0.2 ml PTR (Phosphotungstic acid
reaction reagent), mixed well, followed by the addition of
1.0 ml 0.6 N sodium hydroxide. Reading was taken after
15 min, at 720 nm on spectrophotometer.
Isolation of erythrocyte and hemolysate preparation
The blood samples were centrifuged at 1000 g for 15 min
at 4°C and the isolated red cells were washed 4–5 times with
0.154 M NaCl to remove plasma and buffy coat. After the
final wash, the required packed cells were lysed by hypo-
tonic shock and different dilutions were used as hemolysate.
Hemoglobin estimation [33]
Hemoglobin  content of the erythrocyte was measured
using cyanmethemoglobin method.
Determination of reduced glutathione (GSH) [34]
Packed red cells (0.2 ml) were used in the assay. The GSH
was made to react with 5'5-dithiobis (2-nitrobenzoic acid)
[DTNB], which reacts with sulfhydryl groups, to develop a
stable color. The absorbance was measured at 412 nm and
GSH content was expressed as μmol/gHb.
Quantitation of oxidized glutathione (GSSG) [35]
Erythrocytes lysate was deproteinized with 0.5 M HClO4.
Then estimation was made on the basis of reduction of
GSSG in presence of NADPH and GRx and decrease of
NADPH at 340 nm after initiating the reaction by adding
GRx was taken as an index of GSSG content, which was
evaluated and expressed as μmol/gHb.
Estimation of lipid peroxidation [36]
Packed red cells (0.2 ml) were used for the quantitation
of malondialdehyde (MDA) as thiobarbituric acid reactive
substances (TBARS). Aliquots of 0.2 ml were mixed
thoroughly with 0.8 ml of phosphate buffered saline
(pH 7.4) and 25 μl of butylatedhydroxytoulene solution.
After adding 0.5 ml of 30% trichloroacetic acid, the samples
were placed on ice-bath for 2 h and then centrifuged at
2000 × g at 25°C for 15 min. One ml of supernatant was
mixed with 75 μl of 0.1 M EDTA and 250 μl of 1%
thiobarbituric acid in 0.05 M NaOH and placed on boiling
water for 15 min. After cooling to room temperature, absor-
bance was measured at 532 nm. MDA contents are ex-
pressed as nmol/gHb.
Assay of GPx activity [37]
GPx activity was measured spectrophotometrically at
340 nm in 50 mM phosphate, 5 mM EDTA, pH 7.0
containing 0.3 mM NADPH, 0.3 U/ml GRx, 5 mM GSH,
4 mM sodium azide, 75 μM H2O2 and 10 μl of erythrocyte
lysate in a final reaction mixture of 3 ml. One unit of GPx
was considered to be the amount necessary to oxidize
1 μmol NADPH/min. Activity was expressed as U/gHb.Vit C & E in Regulating Anti and Pro-oxidants in Preeclampsia
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Assay of SOD activity [34]
The assay mixture contained 1M Tris, 5 mM EDTA
buffer, pH 8.0, and 10 mM pyrogallol and the inhibition of
pyrogallol oxidation by SOD was monitored at 420 nm, and
the amount of enzyme producing 50% inhibition was taken
as one unit of enzyme activity (U/gHb).
Assay of catalase activity [38]
The assay mixture contained 1 M Tris, 5 mM EDTA
buffer, pH 7.0 and 200 mM hydrogen peroxide (H2O2).
Disappearance of H2O2 was monitored at 240 nm for 30 s
and the activity of catalase was evaluated and expressed as
kU/gHb.
Assay of GRx activity [39]
The main reagent was prepared by combining 18 ml of
KH2PO4 buffer 139 mM, 0.76 mM EDTA, pH 7.4 and 2 ml
of NADPH 2.5 mM. The sample (20 μl of 1:20
hemolysate + 20 μl of KH2PO4 buffer), 220 μl of the main
reagent and 5 μl of FAD 0.315 mM + 10 μl of KH2PO4
buffer were added to the cuvette and the absorbance at
340 nm was monitored for 200 s (step A). Then 30 μl of
GSSG 22 mM + 10 μl of KH2PO4 buffer were added to start
the reaction and the absorbance was followed for 175 s (step
B). The final reaction volume was 315 μl. The difference in
absorbance per minute between steps B and A was used to
calculate the enzyme activity. The unit in μmol of NADPH
oxidized/min and the GRx activity was evaluated and
expressed as U/gHb.
Statistical analysis
Data were analyzed between placebo-P; and Group A
and Group B by the Student t-test. The data were expressed
as mean ± Standard Deviation. The statistical t-test was
considered significant with a p-value of 0.05 or less. Calcu-
lations of the two-tailed probability: p-values and SEM
(Standard Error of Means) were performed using GraphPad
QuickCalcs Software.
Results
The systolic and diastolic blood pressures of patients
with preeclampsia who were taking or not taking vitamin
supplements were higher (statistically extremely significant
p<0.0001) than those of normotensive patients. This
indicates that the preeclampsia in both the cases was of
severe nature. The preeclamptics presented with proteinuria
& edema, but differences in their average pulse rate were not
Table 1. Demographic and clinical characteristics of three study groups.
Values are expressed as mean ± SD n = number of subjects studied. a (Group A compared to placebo); b (Group B compared to placebo );
c ( Group A compared to Group B).
Parameters
Control 
(Placebo) 
(n = 20)
Preeclamptics (PE) 
without vitamin 
supplements 
Group A (n = 22)
Preeclamptics (PE) 
with vitamin 
supplements 
Group B (n =2 1 )
p values 
(two tailed 
probability)
Statistical 
significance
Age (year) 28.8 ± 7.2 29.2 ± 6.4 27.4 ± 8.4 — —
Mean gestational 
age at sampling 
(weeks)
36.4 ± 1.8 34.4 ± 2.2 33.8 ± 2.4 — —
BMI at sampling 
weight/(height)2 
Kg/(m)2
21.8 ± 3.4 19.3 ± 1.8 20.2 ± 2.6 — —
Systolic BP 
(mmHg)
109.4 ± 8.8 158 ± 14.6 152 ± 12.4 <0.000a (extremely significant)
(SEM = 1.968) (SEM = 3.113) (SEM = 2.706) <0.0001b (extremely significant)
0.1549c (not significant)
Diastolic BP 
(mmHg)
66 ± 8.2 110.4 ± 4.2 103.8 ± 16.8 <0.0001a (extremely significant)
(SEM = 1.834) (SEM = 0.895) (SEM = 3.666) <0.0001b (extremely significant)
0.0815c (not significant)
Pulse rate 
(beats/min)
70.6 ± 2.8 72.6 ± 3.8 70.4 ± 3.6 0.0613a (not significant)
(SEM = 0.626) (SEM = 0.810) (SEM = 0.786) 0.8442b (not significant)
0.0584c (not significant)
Proteinuria 
(gm/day)
Nil 1.78 ± 0.6 0.8 ± 0.4 — —
Edema Nil ++ in all cases ++ in all cases — —M. Suhail et al.
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significant. The demographic and clinical data of these
groups are shown in Table 1.
NO, MDA, NO/MDA ratio
Plasma lipid peroxides (MDA) levels were found to be
elevated in preeclamptics with and without vitamin supple-
ments. Moreover, the increase was significantly higher in
Group A (p = 0.0013) than in Group B (p = 0.0184) as com-
pared to placebo-P (Fig. 1). The nitric oxide contents were
also observed to be at higher levels in preeclamptic women,
but, in this case, the elevation was higher in Group B (highly
significant,  p = 0.003) than in group A (significant,
p = 0.0111) as depicted in Fig. 2. The NO/MDA ratios,
however, were not significantly different in all the three
cases (Fig. 3).
GSH, GSSG, GSSG/GSH and uric acid contents
The amount of reduced glutathione was found to decrease
(p = 0.0099, highly significant) during the development of
preeclamptic conditions. But, this decrease was lesser in
Group B with vitamin supplements. The fall in glutathione
levels is statistically non-significant (p = 0.1233) in Group B
when compared to placebo, however comparison of A
with B showed significant (p = 0.0485) difference (Fig. 4).
Oxidized glutathione was higher (p = 0.0053, highly signifi-
cant) in Group A but this increase was not significant
(p = 0.1419) in Group B (Fig. 5). The ratios of GSSG/GSH
were also evaluated which gave interesting results (Fig. 6).
The ratio increase was higher in Group A (p = 0.003, highly
significant), but it was not significant (p = 0.3483) in Group
B. When groups A and B were compared, however, the
difference was significant (p = 0.0134). Uric acid contents
were found to increase (extremely significant, p<0.0001)
both in Groups A and B as compared to placebo. But there
was not significant difference (p = 0.1813) between Groups
A and B as evident from Fig. 7.
Fig. 1. MDA contents. Columns show mean values. Vertical
bars represent SEM.
P = 6.22 ± 2.8 (SEM = 0.6261) A = 8.48 ± 1.2 (SEM =
0.2558) B = 8.02 ± 1.8 (SEM = 0.3928) Values are
Mean ± SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference highly significant, p = 0.0013);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference significant, p = 0.0184);
Group A compared to Group B (Difference not signifi-
cant, p = 0.3278).
Fig. 2. Nitric oxide contents. Columns show mean values. Verti-
cal bars represent SEM.
P = 19.3 ± 4.2 (SEM = 0.939) A = 23.8 ± 6.4 (SEM =
1.364) B = 24.1 ± 5.4 (SEM = 1.178) Values are mean ±
SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference significant, p = 0.0111);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference highly significant, p = 0.003);
Group A compared to Group B (Difference not signifi-
cant, p = 0.8692).
Fig. 3. Ratio of NO/MDA. Columns show mean values. Vertical
bars represent SEM.
P = 3.103 ± 0.8 (SEM = 0.1789) A = 2.807 ± 0.6 (SEM =
0.1279) B = 3.005 ± 0.5 (SEM = 0.1091) Values are
mean ± SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference not significant, p = 0.18);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference not significant, p = 0.6389);
Group A compared to Group B (Difference not signifi-
cant, p = 0.2477).Vit C & E in Regulating Anti and Pro-oxidants in Preeclampsia
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Variations in the activities of key enzymes involved in
antioxidative actions
The activity of SOD decreased significantly (p<0.0001,
extremely significant) in preeclamptics not taking vitamins,
whereas the decrease was simply significant (p = 0.002) for
those taking vitamins. There was a significant difference
(p = 0.0434) between these two Groups (Fig. 8). Comparison
of the activity of GPx in all the three Groups revealed no
significant changes (Fig. 9). But, interesting alterations were
found in the activities of GRx, which decreased significantly
Fig. 4. Reduced glutathione contents. Columns show mean val-
ues. Vertical bars represent SEM.
P=1 0 . 4 2± 2.81 (SEM = 0.6283) A = 8.02 ± 2.92 (SEM =
0.6225) B = 9.39 ± 1.02 (SEM = 0.2226) Values are
mean ± SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference highly significant, p = 0.0099);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference not significant, p = 0.1233);
Group A compared to Group B (Difference significant,
p = 0.0485).
Fig. 5. Oxidized glutathione contents. Columns show mean val-
ues. Vertical bars represent SEM.
P = 0.98 ± 0.28 (SEM = 0.0626) A = 1.24 ± 0.29 (SEM =
0.0618) B = 1.08 ± 0.12 (SEM = 0.0262). Values are
mean ± SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference highly significant, p = 0.0053);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference not significant, p = 0.1419);
Group A compared to Group B (Difference significant,
p = 0.0241).
Fig. 6. Ratio of GSSG/GSH in three groups. Columns show
mean values. Vertical bars represent SEM.
P = 0.0941 ± 0.08 (SEM = 0.01789) A = 0.155 ± 0.04
(SEM = 0.00853) B = 0.115 ± 0.06 (SEM = 0.01309)
Values are mean ± SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference highly significant, p = 0.003);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference not significant, p = 0.3483);
Group A compared to Group B (Difference significant,
p = 0.0134).
Fig. 7. Uric acid contents. Columns show mean values. Vertical
bars represent SEM.
P = 6.5 ± 1.02 (SEM = 0.2281) A = 9.2 ± 1.84 (SEM =
0.3923) B = 8.5 ± 1.51 (SEM = 0.3295). Values are
Mean ± SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference extremely significant, p<0.0001);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference extremely significant, p<0.0001);
Group A compared to Group B (Difference not signifi-
cant, p = 0.1813).M. Suhail et al.
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(p = 0.0138) in preeclamptics not having used vitamins.
Those who consumed vitamin E and C during the gestational
period from the second trimester of pregnancy to delivery
demonstrated an insignificant (p = 0.5395) fall in GRx
activities.
However, comparisons between Groups A and B showed
a significant (p = 0.05) difference in GRx activities
(Fig. 10). Catalase activities were elevated in both Groups A
and B as compared to placebo, and the increase was found to
be highly significant (p = 0.0084 and p = 0.0066, respec-
tively), whereas no statistically significant difference
(p = 0.8555) was observed between Groups A and B, as
depicted in Fig. 11.
Discussion
NO, MDA and NO/MDA ratio
NO plays an important role in the pathogenesis of PE as
Fig. 8. Superoxide dismutase activities. Columns show mean
values. Vertical bars represent SEM.
P = 710 ± 90.6 (SEM = 20.259) A = 548 ± 92.8 (SEM =
19.785) B = 610 ± 102.2 (SEM = 22.302). Values are
Mean ± SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference extremely significant, p<0.0001);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference highly significant, p = 0.002);
Group A compared to Group B (Difference significant,
p = 0.0434).
Fig. 9. Glutathione peroxidase activities. Columns show mean
values. Vertical bars represent SEM.
P = 14.6 ± 3.8 (SEM = 0.85) A = 12.8 ± 3.2 (SEM =
0.682) B = 13.2 ± 4.8 (SEM = 1.047). Values are Mean ±
SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference not significant, p = 0.1036);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference not significant, p = 0.3084);
Group A compared to Group B (Difference not signifi-
cant, p = 0.7484).
Fig. 10. Glutathione reductase activities. Columns show mean
values. Vertical bars represent SEM.
P=1 1 . 2± 3.08 (SEM = 0.6887) A = 8.22 ± 4.26 (SEM =
0.9082) B = 10.58 ± 3.32 (SEM = 0.7245). Vales are
Mean ± SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference significant, p = 0.0138);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference not significant, p = 0.5395);
Group A compared to Group B (Difference significant,
p = 0.05).
Fig. 11. Catalase activities. Columns show mean values. Vertical
bars represent SEM.
P = 98.2 ± 30.4 (SEM = 6.798) A = 124.8 ± 31.6 (SEM =
6.737) B = 126.6 ± 32.8 (SEM = 7.158). Values are
Mean ± SD.
Group A- PE without Vit. Supplements compared to
placebo-P (Difference highly significant, p = 0.0084);
Group B- PE with Vit. Supplements compared to placebo-
P (Difference highly significant p = 0.0066);
Group A compared to Group B (Difference not signifi-
cant, p = 0.8555).Vit C & E in Regulating Anti and Pro-oxidants in Preeclampsia
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the enhanced level of oxidative stress associated with the
conditions increases the concentration of superoxide that
reacts with NO to produce peroxynitrite (ONOO−), reducing
the level of available NO. Peroxynitrite is a potentially
harmful ROS as it causes nitrosylation of tyrosine residues,
leading to changes in protein conformation and inactivation.
Preeclampsia is associated with increased nitrotyrosine
residues in placental villous vascular endothelium [40]. The
effect of elevation in peroxynitrite and reduced bioavail-
ability of NO, resulting from enhanced production of free
radicals and the resultant placental oxidative state, may
contribute to the elevation of maternal blood pressure,
proteinuria, platelet dysfunction and alteration in the level of
thromboxane, prostacyclin and endothelin characteristic of
preeclampsia [41]. Another common source of placental
oxidative damage is the peroxidation of membrane phospho-
lipids that exerts a variety of effects within placenta. Our
results on NO contents showed an increase of about 23–25%
in preeclamptics, but the bioavailability of NO might have
been blocked, as there was an increase of 29–36% in MDA
contents.
The oxidative destruction of polyunsaturated fatty acids
(PUFAs) of phospholipids, known as lipid peroxidation, can
be in fact considered as a hallmark of oxidative stress.
PUFAs are important for the normal function of most of the
cells. MDA, an end product of lipid peroxidation induced by
ROS, is well correlated with the degree of lipid peroxidation
[28,  29]. The result mentioned above revealed a highly
significant increase in MDA content in preeclamptic patients
in comparison to normal placebo. This may result in a
greater potential for endothelial damage ultimately leading
to elevated diastolic pressure [19]. Enhanced ROS in turn
can oxidize many other important biomolecules including
erythrocyte membrane phospholipids. Thus, lipid peroxides
and free radicals may be important in the pathogenesis of
preeclampsia. Our results on MDA contents were consistent
with the observations of other workers [31,  19] as well.
The increase in MDA content in patients who took vitamin
(group B) was simply significant (29%) when compared to
group A in which it was very significant (36%). This shows
the effectiveness of vitamins C and E in restricting the
elevation of lipid peroxidation. Our results on NO contents
were in agreement with the findings of other investigators
[20,  21]. Although levels of NO in preeclamptics, both
without and with vitamin had increased significantly and
highly significantly, respectively, there was no distinct
improvement in blood pressure symptoms for either group.
This shows that bioavailability of NO was restricted,
perhaps due to its enhanced reaction with superoxide
resulting in peroxynitrite (ONOO−) as mentioned above.
The pathogenic link of serum uric acid is evident from
other studies [25, 26] and our results are consistent with their
reports as the increase in uric acid contents in both groups
A and B were found to be extremely significant.
GSH, GSSG, GSSG/GSH ratio
Glutathione and glutathione related enzymes are one of
the major antioxidant systems within body. GSH is the most
abundant thiol-based antioxidant, and is found primarily in
the reduced form, with intracellular concentration up to
11 mM and provides sulfhydryl-buffering capacity. It also
conveys an antioxidant power through the direct inactivation
of ROS or by acting as an electron donor for GPx that
reduces H2O2 to water [42]. It has been suggested that the
high levels of GSH may act as a compensatory mechanism
in preeclampsia to prevent excessive lipid peroxidation via
membrane bound GPx [43]. In our study the erythrocyte
GSSG concentration was very significantly elevated in
preeclamptics, and we observed a significant increase in the
redox potential values for the pair GSSG/GSH as compared
to placebo, showing altered antioxidant balance. Our data
clearly indicate that GSH in red blood cells decreased
profoundly in preeclamptic pathophysiological conditions
with a parallel increase in MDA and GSSG concentration.
Our findings on MDA, GSH and GSSG are in agreement
with those reported earlier [44].
SOD, GPx, catalase and GRx
SOD, catalase and GPx are important factors in the
antioxidative defense system. SOD protects and revitalizes
cells and reduces the rate of cell destruction. It neutralizes
some of the most dangerous free radicals, the superoxide
radicals, before they can wreak havoc on the body. Super-
oxide generation also perpetuates oxidative stress and lipid
peroxidation through the oxidation of mitochondrial iron-
sulphur clusters such as aconitase, which subsequently
stimulate membrane phospholipid peroxidation by alkoxyl
radicals [45]. Deficient SOD activity may also increase
oxidative insult by promoting the interaction of NO and
superoxide to produce peroxynitrite as mentioned earlier.
Superoxide dismutase and nitric oxide compete for super-
oxide. A consequence of SOD deficiency is an increase in
nitric oxide interactions with superoxide, which results in
the generation of peroxynitrite, subsequently reducing
vasodilation through the impairment of NO and increasing
ONOO− induced lipid peroxidation [41]. Our results on SOD
activity clearly indicate an extremely significant decline
(23%) in its activity in preeclamptic patients (Group A) and
a significant decrease (14%) in preeclamptics using vitamin
(Group B); a significant difference was observed between
these two Groups (10–11%). From our results we infer the
positive effect of vitamins C and E on retaining SOD activity
during preeclampsia.
The principal function of GPx is to protect against
damage from the endogenously produced hydroxyperoxides
and to catalyze the reduction of hydroxyperoxides byM. Suhail et al.
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glutathione. Catalase promotes the conversion of hydrogen
peroxide, a powerful and potentially harmful oxidizing
agent, to water and molecular oxygen. It also uses H2O2 to
oxidize toxins such as phenols, formic acid, formaldehyde
and alcohols. Catalase, along-with SOD and GPx, controls
the levels of oxygen-derived free radicals in cells. Our
results show non-significant alterations in GPx activities.
The activity of catalase increased very significantly in both
Groups A and B (27% and 29% increase respectively),
which shows its compensatory regulation in response to
increased oxidative stress. No effect of vitamins C and E,
however, was observed on GPx levels. GRx activity
declined significantly (27%) in preeclamptics who had not
consumed vitamins C and E (Group A), but its activity did
not fall significantly (5.5%) in patients who had used these
vitamins regularly as mentioned above. A comparison of
these two Groups revealed a significant difference (22–29%),
which shows that vitamins C and E consumption prevented
the fall in GRx activity. This finding shows a clear correla-
tion with the levels of GSH, which is evident from our
results on GSH, GSSG and GSSG/GSH.
In conclusion, we hypothesize enhanced oxidative stress
in preeclampsia, on the basis of our results showing
decreased SOD, GRx and GPx activities, with resulting
inefficient control of the higher levels of oxygen free
radicals produced. The increased activity of catalase that
we observed may be a compensatory regulation in response
to increased oxidative stress. Increased catalase activity
could be interpreted as a futile effort to counteract the
overproduction of reactive oxygen species, and to provide a
relief to enhanced oxidative damage in preeclampsia. Lipid
peroxides could participate in the cytotoxic mechanism
leading to endothelial injury and enhanced blood pressure.
The decreased concentration of glutathione supports the
hypothesis that lipid peroxidation is an important factor in
the pathogenesis of PE. Chappell et al. [1] have reported
that a significant reduction in the incidence of preeclampsia
was found in women at risk who were taking a vitamins C
and E supplements. They inferred a correlation between the
PAI-1/PAI-2 (plasminogen activator inhibitor) ratio with
vitamins C and E levels. Furthermore, they [2] suggested
that antioxidant supplementation in women who were at
risk of preeclampsia was associated with improvement in
biochemical indices of the disease. Zhang et al. [7] have
reported a 2-fold increased risk of developing preeclampsia
in women taking lower vitamin C doses. Several reports
reviewed by Rodrigo et al. [9] suggest the prophylactic use
of vitamins C and E before the 20th. week of gestation, after
identifying the risk factors on the basis of history of the
patient, what would lower the risk of maternal vascular
dysfunction and therein the onset of PE.
We found that the patients supplemented with vitamin C
1000 mg plus vitamin E 400 IU daily from the second
trimester of pregnancy until delivery showed improvements
in certain biochemical indices during the development of
preeclampsia. The elevation in MDA content was found to
be significantly lower. Oxidation of reduced glutathione to
GSSG was inhibited to a greater extent. The activities of
antioxidant enzymes were also influenced by the use of
vitamins C and E. The reduction of SOD activity during
the development of preeclampsia was controlled as a
consequence of vitamin consumption: the decrease was
found to be 14% whereas it was 23% in patients who had
not used vitamins C and E. The most prominent effect of
the use of these vitamins was found to be associated with the
activity of glutathione reductase. Reduction in its activity
was much higher 27% as compared to that in patients who
were taking vitamins (5.5%). Thus, we conclude that use of
vitamins C and E definitely controls certain important
biochemical indices during the development of pre-
eclampsia, and that further studies are needed to develop
strategies for the prevention of preeclampsia in women at
high risk.
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